Memphis Pharmaceuticals results, Q1 2025
Net profit, assets, equity and cash flow for Q1 2025, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit141 millionEGP · +468.8% vs the same period a year earlier
Total assets1.33 billionEGP · +67.2% vs the same period a year earlier
Shareholders' equity289 millionEGP · +125.1% vs the same period a year earlier
Operating cash flow97.87 millionEGP · −28.7% vs the same period a year earlier
In short
- Memphis Pharmaceuticals's net profit for Q1 2025 was about 141 million EGP, up +468.8% from 24.76 million EGP in Q1 2024.
- Total assets at the end of Q1 2025 were about 1.33 billion EGP, and shareholders' equity about 289 million EGP.
- Operating cash flow for Q1 2025 was positive at 97.87 million EGP.
Key lines against the same period a year earlier
This periodQ1 2024Change
Net profit141 million24.76 million+468.8%
Gross profit191 million55.09 million+247.4%
Total assets1.33 billion796 million+67.2%
Total liabilities1.04 billion668 million+56.1%
Shareholders' equity289 million128 million+125.1%
Total liabilities and equity1.33 billion796 million+67.2%
Operating cash flow97.87 million137 million−28.7%
Investing cash flow27.99 million3.31 million+745.6%
Financing cash flow-33.75 million——
Net change in cash92.11 million141 million−34.5%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy